ID

26939

Beschreibung

CADY Study ICORG 08-01; ODM derived from: https://clinicaltrials.gov/show/NCT00968682

Link

https://clinicaltrials.gov/show/NCT00968682

Stichworte

Versionen (1)
  1. 28.10.17 28.10.17 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

28. Oktober 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00968682

Englisch

Eligibility Breast Cancer NCT00968682

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. her-2 positive breast cancer by immunohistochemistry and/or fluorescence in-situ hybridisation.
Beschreibung

HER2-positive carcinoma of breast Immunohistochemistry | HER2-positive carcinoma of breast Fluorescent in Situ Hybridization

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1960398
UMLS CUI [1,2]
C0021044
UMLS CUI [2,1]
C1960398
UMLS CUI [2,2]
C0162789
2. planned neoadjuvant and/or adjuvant treatment with chemotherapy and trastuzumab either sequentially or in combination or single agent trastuzumab.
Beschreibung

Neoadjuvant Chemotherapy Planned | Adjuvant Chemotherapy Planned | trastuzumab | Combined Modality Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0600558
UMLS CUI [1,3]
C1301732
UMLS CUI [2,1]
C0085533
UMLS CUI [2,2]
C1301732
UMLS CUI [3]
C0728747
UMLS CUI [4]
C0009429
3. 18 years of age or older.
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
4. disease stage i-iii, whose treatment plan includes trastuzumab either sequentially, in combination or as a single agent will be eligible for inclusion in the study.
Beschreibung

Disease TNM Breast tumor staging | trastuzumab | Combined Modality Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0474926
UMLS CUI [2]
C0728747
UMLS CUI [3]
C0009429
5. as this is a non-interventional study, patients enrolled in therapeutic clinical trials will also be eligible for inclusion.
Beschreibung

Study Subject Participation Status | Therapeutic Clinical Trial

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C1515364
6. treatment with curative intent.
Beschreibung

Curative procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C1276305
7. ecog performance status 0, 1 or 2.
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
8. adequate cardiac function, with muga or echocardiograph > 50%.
Beschreibung

Cardiac function MUGA | Cardiac function Echocardiography

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0232164
UMLS CUI [1,2]
C0521317
UMLS CUI [2,1]
C0232164
UMLS CUI [2,2]
C0013516
9. written informed consent.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. presence of a medical or psychiatric condition, which, in the opinion of the investigator, would potentially pose a risk to the patient by participating in this trial.
Beschreibung

Medical condition Study Subject Participation Status At risk Patient | Mental condition Study Subject Participation Status At risk Patient

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1444641
UMLS CUI [1,4]
C0030705
UMLS CUI [2,1]
C3840291
UMLS CUI [2,2]
C2348568
UMLS CUI [2,3]
C1444641
UMLS CUI [2,4]
C0030705
2. evidence of metastatic disease.
Beschreibung

Neoplasm Metastasis

Datentyp

boolean

Alias
UMLS CUI [1]
C0027627
3. patients with uncontrolled hypertension (sustained systolic blood pressure >180mmhg or diastolic blood pressure >100mmhg), significant valvular disease (aortic or mitral regurgitation of 3 or 4+/ 4+ severity or stenosis of either valve), history of uncontrolled cardiac arrhythmias, prior symptomatic or asymptomatic myocardial infarction or angina pectoris requiring anti-anginal medication.
Beschreibung

Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure | Valvular disease | Aortic regurgitation Grade | Mitral regurgitation Grade | Aortic Valve Stenosis | Mitral Valve Stenosis | Cardiac Arrhythmia Uncontrolled | Myocardial Infarction Symptomatic | Myocardial Infarction Asymptomatic | Angina Pectoris Requirement Antianginals

Datentyp

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C0871470
UMLS CUI [3]
C0428883
UMLS CUI [4]
C3258293
UMLS CUI [5,1]
C0003504
UMLS CUI [5,2]
C0441800
UMLS CUI [6,1]
C0026266
UMLS CUI [6,2]
C0441800
UMLS CUI [7]
C0003507
UMLS CUI [8]
C0026269
UMLS CUI [9,1]
C0003811
UMLS CUI [9,2]
C0205318
UMLS CUI [10,1]
C0027051
UMLS CUI [10,2]
C0231220
UMLS CUI [11,1]
C0027051
UMLS CUI [11,2]
C0231221
UMLS CUI [12,1]
C0002962
UMLS CUI [12,2]
C1514873
UMLS CUI [12,3]
C3537168
4. prior anthracycline or trastuzumab therapy.
Beschreibung

Anthracyclines | trastuzumab

Datentyp

boolean

Alias
UMLS CUI [1]
C0282564
UMLS CUI [2]
C0728747
5. inability to give informed consent for any reason.
Beschreibung

Informed Consent Unable

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Breast Cancer NCT00968682

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
HER2-positive carcinoma of breast Immunohistochemistry | HER2-positive carcinoma of breast Fluorescent in Situ Hybridization
Item
1. her-2 positive breast cancer by immunohistochemistry and/or fluorescence in-situ hybridisation.
boolean
C1960398 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C1960398 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
Neoadjuvant Chemotherapy Planned | Adjuvant Chemotherapy Planned | trastuzumab | Combined Modality Therapy
Item
2. planned neoadjuvant and/or adjuvant treatment with chemotherapy and trastuzumab either sequentially or in combination or single agent trastuzumab.
boolean
C0392920 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C0085533 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
C0728747 (UMLS CUI [3])
C0009429 (UMLS CUI [4])
Age
Item
3. 18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Disease TNM Breast tumor staging | trastuzumab | Combined Modality Therapy
Item
4. disease stage i-iii, whose treatment plan includes trastuzumab either sequentially, in combination or as a single agent will be eligible for inclusion in the study.
boolean
C0012634 (UMLS CUI [1,1])
C0474926 (UMLS CUI [1,2])
C0728747 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Study Subject Participation Status | Therapeutic Clinical Trial
Item
5. as this is a non-interventional study, patients enrolled in therapeutic clinical trials will also be eligible for inclusion.
boolean
C2348568 (UMLS CUI [1])
C1515364 (UMLS CUI [2])
Curative procedure
Item
6. treatment with curative intent.
boolean
C1276305 (UMLS CUI [1])
ECOG performance status
Item
7. ecog performance status 0, 1 or 2.
boolean
C1520224 (UMLS CUI [1])
Cardiac function MUGA | Cardiac function Echocardiography
Item
8. adequate cardiac function, with muga or echocardiograph > 50%.
boolean
C0232164 (UMLS CUI [1,1])
C0521317 (UMLS CUI [1,2])
C0232164 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
Informed Consent
Item
9. written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Medical condition Study Subject Participation Status At risk Patient | Mental condition Study Subject Participation Status At risk Patient
Item
1. presence of a medical or psychiatric condition, which, in the opinion of the investigator, would potentially pose a risk to the patient by participating in this trial.
boolean
C3843040 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0030705 (UMLS CUI [1,4])
C3840291 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444641 (UMLS CUI [2,3])
C0030705 (UMLS CUI [2,4])
Neoplasm Metastasis
Item
2. evidence of metastatic disease.
boolean
C0027627 (UMLS CUI [1])
Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure | Valvular disease | Aortic regurgitation Grade | Mitral regurgitation Grade | Aortic Valve Stenosis | Mitral Valve Stenosis | Cardiac Arrhythmia Uncontrolled | Myocardial Infarction Symptomatic | Myocardial Infarction Asymptomatic | Angina Pectoris Requirement Antianginals
Item
3. patients with uncontrolled hypertension (sustained systolic blood pressure >180mmhg or diastolic blood pressure >100mmhg), significant valvular disease (aortic or mitral regurgitation of 3 or 4+/ 4+ severity or stenosis of either valve), history of uncontrolled cardiac arrhythmias, prior symptomatic or asymptomatic myocardial infarction or angina pectoris requiring anti-anginal medication.
boolean
C1868885 (UMLS CUI [1])
C0871470 (UMLS CUI [2])
C0428883 (UMLS CUI [3])
C3258293 (UMLS CUI [4])
C0003504 (UMLS CUI [5,1])
C0441800 (UMLS CUI [5,2])
C0026266 (UMLS CUI [6,1])
C0441800 (UMLS CUI [6,2])
C0003507 (UMLS CUI [7])
C0026269 (UMLS CUI [8])
C0003811 (UMLS CUI [9,1])
C0205318 (UMLS CUI [9,2])
C0027051 (UMLS CUI [10,1])
C0231220 (UMLS CUI [10,2])
C0027051 (UMLS CUI [11,1])
C0231221 (UMLS CUI [11,2])
C0002962 (UMLS CUI [12,1])
C1514873 (UMLS CUI [12,2])
C3537168 (UMLS CUI [12,3])
Anthracyclines | trastuzumab
Item
4. prior anthracycline or trastuzumab therapy.
boolean
C0282564 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
Informed Consent Unable
Item
5. inability to give informed consent for any reason.
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video